Caboxen cabozantinib 80 MG

Cabozantinib is a targeted therapy. It is an oral receptor tyrosine kinase inhibitor. Cabozantinib treats metastatic medullary thyroid cancer (MTC), advanced renal cell carcinoma, and patients with hepatocellular cancer (HCC) who have previously received sorafenib.

1 thought on “Caboxen cabozantinib 80 MG”

Leave a Comment